SciELO - Scientific Electronic Library Online

 
vol.76 número1Tratamiento quirúrgico de la ventana aortopulmonar: 15 años de experiencia índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Pediatría

versión impresa ISSN 0034-7531versión On-line ISSN 1561-3119

Resumen

DE LA GUARDIA PENA, Odalis María; ESPINASO KUAN, Joan; PLANAS VIATEL, Tarsis  y  SABIGNE LAMOTE, Magdalena. Jalea Real (tabletas masticables) una alternativa en el tratamiento de pacientes pediátricos con inmunodeficiencia celular. Rev Cubana Pediatr [online]. 2004, vol.76, n.1. ISSN 0034-7531.

In order to evaluate the efficacy of the use of Royal Jelly (chewable tablets) in children with cellular immunodeficiencies, 100 children that were diagnosed this affection at the Immunology Department of "Juan Cruz Martínez Maceira" Northern Children Teaching Hospital, in Santiago de Cuba, from 200 to 2002, were studied. 3 groups of treatment were established: group 1, usual treatment with levamisol and vitamins; group 2, usual treatment plus half of the optimun dose of Royal Jelly; group 3, Royal Jelly at optimum dose. A higher clinical and laboratory improvement was observed among patients using Royal Jelly. No adverse reactions were detected and there was an increase of the quality of life and of appetite . A rise of the peripheral T lymphocytes count was also proved by Roseta test. When the Royal Jelly was mixed with levamisol, the appearance of neutropenia decreased considerably. According to the results of this study, the Royal Jelly may be used as a cellular immunomodulator.

Palabras clave : BEES; INMUNOLOGIC DEFICIENCY SYNDROMES [drug therapy]; TABLETS [therapeutic use]; PLANT EXTRACTS [therapeutic use]; CHILD.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons